F O Nestle

Summary

Affiliation: University of Zurich
Country: Switzerland

Publications

  1. ncbi request reprint Vaccines and melanoma
    F O Nestle
    Department of Dermatology, University of Zurich Hospital, Germany
    Clin Exp Dermatol 27:597-601. 2002
  2. ncbi request reprint Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen
    Michel Gilliet
    Department of Dermatology, University of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Blood 102:36-42. 2003
  3. ncbi request reprint Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells
    Tanja Maier
    Department of Dermatology, University Hospital Zurich, Switzerland
    Blood 102:2338-44. 2003
  4. pmc Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions
    Gianni Gerlini
    Department of Dermatological Sciences, University of Florence Medical School, Florence, Italy
    Am J Pathol 165:1853-63. 2004
  5. ncbi request reprint Occupational dermatoses in cheese makers: frequent association of irritant, allergic and protein contact dermatitis
    F O Nestle
    Department of Dermatology, University of Zurich Medical School, Switzerland
    Dermatology 194:243-6. 1997
  6. ncbi request reprint Metallurgy: high nickel release from 1- and 2-euro coins
    Frank O Nestle
    Department of Dermatology, University of Zurich Hospital, Zürich 8901, Switzerland
    Nature 419:132. 2002
  7. ncbi request reprint Dendritic-cell-based therapeutic vaccination against cancer
    Frank O Nestle
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Curr Opin Immunol 17:163-9. 2005
  8. ncbi request reprint Dendritic cell therapy for skin cancer
    F O Nestle
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Vox Sang 87:112-4. 2004
  9. ncbi request reprint [Concepts for immune intervention in psoriasis vulgaris]
    F O Nestle
    Dermatologische Klinik des Universitätsspitals Zürich
    Praxis (Bern 1994) 89:1468-70. 2000
  10. ncbi request reprint Dendritic cells: role in skin diseases and therapeutic applications
    F O Nestle
    Department of Dermatology, University of Zurich Medical School, Zurich, Switzerland
    Clin Exp Dermatol 24:204-7. 1999

Collaborators

Detail Information

Publications45

  1. ncbi request reprint Vaccines and melanoma
    F O Nestle
    Department of Dermatology, University of Zurich Hospital, Germany
    Clin Exp Dermatol 27:597-601. 2002
    ..These and other advances in the field of melanoma vaccines will be discussed...
  2. ncbi request reprint Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen
    Michel Gilliet
    Department of Dermatology, University of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Blood 102:36-42. 2003
    ..Our results indicate that intranodal vaccination with semimature DCs can prime strong, long-lasting CD4 T-cell responses with a TH1-type cytokine profile in cancer patients...
  3. ncbi request reprint Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells
    Tanja Maier
    Department of Dermatology, University Hospital Zurich, Switzerland
    Blood 102:2338-44. 2003
    ..Intranodal injection of autologous tumor-lysate-pulsed DCs is well-tolerated and achieves immunologic and objective clinical responses in selected CTCL patients...
  4. pmc Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions
    Gianni Gerlini
    Department of Dermatological Sciences, University of Florence Medical School, Florence, Italy
    Am J Pathol 165:1853-63. 2004
    ..Our findings suggest that metastatic but not primary melanomas can down-regulate CD1 molecules on infiltrating dendritic cells by secreting IL-10 which may represent a novel way to escape the immune response directed against the tumor...
  5. ncbi request reprint Occupational dermatoses in cheese makers: frequent association of irritant, allergic and protein contact dermatitis
    F O Nestle
    Department of Dermatology, University of Zurich Medical School, Switzerland
    Dermatology 194:243-6. 1997
    ..Few data are available on occupational dermatoses in cheese makers...
  6. ncbi request reprint Metallurgy: high nickel release from 1- and 2-euro coins
    Frank O Nestle
    Department of Dermatology, University of Zurich Hospital, Zürich 8901, Switzerland
    Nature 419:132. 2002
    ..A factor contributing to this high release of nickel is corrosion due to the bimetallic structure of these coins, which generates a galvanic potential of 30-40 mV in human sweat...
  7. ncbi request reprint Dendritic-cell-based therapeutic vaccination against cancer
    Frank O Nestle
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Curr Opin Immunol 17:163-9. 2005
    ..This explains the current need for innovative well designed trials with defined endpoints that induce robust anti-tumor immunity...
  8. ncbi request reprint Dendritic cell therapy for skin cancer
    F O Nestle
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Vox Sang 87:112-4. 2004
  9. ncbi request reprint [Concepts for immune intervention in psoriasis vulgaris]
    F O Nestle
    Dermatologische Klinik des Universitätsspitals Zürich
    Praxis (Bern 1994) 89:1468-70. 2000
    ..Concepts for immunointervention will be introduced...
  10. ncbi request reprint Dendritic cells: role in skin diseases and therapeutic applications
    F O Nestle
    Department of Dermatology, University of Zurich Medical School, Zurich, Switzerland
    Clin Exp Dermatol 24:204-7. 1999
    ..This short review attempts to follow some of the origins of dendritic cell research with special regard to dermatology and gives a perspective on newer developments such as the use of dendritic cells to induce antigen-specific tolerance...
  11. ncbi request reprint Clinical efficacy of narrow-band UVB (311 nm) combined with dithranol in psoriasis. An open pilot study
    P Carrozza
    Department of Dermatology, University Hospital Zurich, Switzerland
    Dermatology 200:35-9. 2000
    ..For UVB, the most effective wavelength in clearing psoriatic lesions was found to be of 313 nm. The efficacy of whole body exposure to narrow-band UVB (311 nm) combined with dithranol in psoriasis has not been evaluated to date...
  12. ncbi request reprint TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis
    J Kamarashev
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Int J Cancer 95:23-8. 2001
    ..Abnormalities in antigen presentation may account for the lack of absolute correlation between tumor thickness and prognosis...
  13. pmc Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells
    A Farkas
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Br J Dermatol 158:921-9. 2008
    ..IFN-DCs potentially mimic DC populations involved in psoriasis and express a wide range of Toll-like receptor (TLR) subtypes...
  14. ncbi request reprint Current state and perspectives of dendritic cell vaccination in cancer immunotherapy
    A Farkas
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Skin Pharmacol Physiol 19:124-31. 2006
    ..This review focuses on the different parameters of dendritic cell biology relevant to cancer immunotherapy and on innovative approaches to hopefully enhance the efficacy of dendritic cell vaccination...
  15. ncbi request reprint Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis
    O Boyman
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Br J Dermatol 152:1211-8. 2005
    ....
  16. ncbi request reprint Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatment
    G F Hofbauer
    Department of Dermatology, University Hospital, , Switzerland
    Dermatology 203:168-70. 2001
    ..burgdorferi titers. After antibiotic therapy, clinical remission and a subsequent drop in B. burgdorferi antibody titers were obtained...
  17. ncbi request reprint Cd1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells
    G Gerlini
    Department of Dermatology, , , Switzerland
    J Invest Dermatol 117:576-82. 2001
    ..Differential expression of CD1 molecules depending on culture conditions might have an impact on clinical applications of dendritic cells for immunotherapy...
  18. ncbi request reprint Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept
    J Kamarashev
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Dermatology 205:213-6. 2002
    ..We conclude that etanercept may be a safe and effective therapy not only in severe psoriatic arthritis, but also in cases of pustular rebound after withdrawal of immunosuppressive agents...
  19. ncbi request reprint Dendritic cells: On the move from bench to bedside
    F O Nestle
    Department of Dermatology, , , Switzerland
    Nat Med 7:761-5. 2001
    ..As dendritic cells increasingly become the adjuvant of choice in new approaches to cancer immunotherapy, a degree of protocol standardization is required to aid future large-scale clinical trials...
  20. pmc Cancer vaccines: the next generation of tools to monitor the anticancer immune response
    Frank O Nestle
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    PLoS Med 2:e339. 2005
  21. ncbi request reprint Treatment of verrucous carcinoma with imiquimod and CO2 laser ablation
    L M Heinzerling
    University Hospital Zurich, Zurich, Switzerland
    Dermatology 207:119-22. 2003
    ..In a third session, tumor parts in the anal canal were vaporized. This case demonstrates that the combination of imiquimod and CO2 laser ablation is an effective treatment option for verrucous carcinoma...
  22. ncbi request reprint Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis
    M Gilliet
    Department of Dermatology, Zurich University Hospital, Gloriastrasse 31, 8091 Zurich, Switzerland
    Br J Dermatol 152:531-6. 2005
    ..The aetiology and pathogenesis remain largely unknown. As a consequence, therapeutic measures with proven efficacy are nonexistent to date...
  23. ncbi request reprint Monoclonal rearrangement of the T cell receptor gamma-chain in lichenoid pigmented purpuric dermatitis of gougerot-blum responding to topical corticosteroid therapy
    P Lor
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Dermatology 205:191-3. 2002
    ..However, prompt clinical response to topical steroid therapy supports the benign clinical nature of our case...
  24. ncbi request reprint Bilateral carpal tunnel syndrome as a clue for the diagnosis of systemic amyloidosis
    F O Nestle
    Department of Dermatology, University of Zurich Medical School, Zurich, Switzerland
    Dermatology 202:353-5. 2001
    ..The coexistence of the specific symptoms of CTS, macroglossia and cutaneous lesions should immediately alert the physician to the probable existence of plasma-cell-dyscrasia-related systemic amyloidosis...
  25. ncbi request reprint Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial
    K Reich
    Department of Dermatology, Georg August University, Gottingen, Germany
    Br J Dermatol 154:1161-8. 2006
    ..Psoriasis has a well-documented, markedly negative effect on patient quality of life...
  26. ncbi request reprint The alphavbeta5 integrin of hematopoietic and nonhematopoietic cells is a transduction receptor of RGD-4C fiber-modified adenoviruses
    H Nagel
    Institute of Molecular Biology, University of Zurich, Zurich, Switzerland
    Gene Ther 10:1643-53. 2003
    ..The RGD-4C vectors further extend the tropism of Ads towards potential human therapies...
  27. ncbi request reprint Histological, immunological and molecular features of a nasal mucosa primary melanoma associated with nasal melanosis
    G F L Hofbauer
    Department of Dermatology, Head and Neck Surgery, University Hospital, Gloriastrasse 31, 8091 Zurich, Switzerland
    Melanoma Res 12:77-82. 2002
    ..Pathways of tumour escape, such as expression of CD54 and interleukin-10, were observed. The clinical, immunological and molecular features suggest that nasal melanosis should be followed closely...
  28. ncbi request reprint Dendritic cell-based cancer therapy
    Curdin Conrad
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Curr Opin Mol Ther 5:405-12. 2003
    ....
  29. ncbi request reprint Dendritic cell vaccination for the treatment of skin cancer
    Frank O Nestle
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Recent Results Cancer Res 160:165-9. 2002
    ..In recent years an enormous increase in our understanding of DC biology has opened up new ways of applying these cells for immunotherapy of cancer...
  30. pmc Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production
    Frank O Nestle
    Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland
    J Exp Med 202:135-43. 2005
    ..These findings uncover a novel innate immune pathway for triggering a common human autoimmune disease and suggest that PDCs and PDC-derived IFN-alpha represent potential early targets for the treatment of psoriasis...
  31. ncbi request reprint Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors
    Michel Gilliet
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Arch Dermatol 140:1490-5. 2004
    ..It has been proposed that the innate immune system plays a central role in driving the autoimmune T-cell cascade leading to psoriasis; however, there is no direct evidence for this...
  32. ncbi request reprint Animal models of psoriasis and psoriatic arthritis: an update
    Curdin Conrad
    Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland
    Curr Rheumatol Rep 8:342-7. 2006
    ..Every mouse model has strengths and weaknesses, with room for improvement. Still, these models will accelerate knowledge of psoriasis pathogenesis and aid in the development of new therapeutics...
  33. ncbi request reprint Immunopathogenesis of psoriasis
    Brian J Nickoloff
    Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
    Clin Rev Allergy Immunol 33:45-56. 2007
    ....
  34. ncbi request reprint Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
    Roberto Lande
    Department of Immunology, M D Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA
    Nature 449:564-9. 2007
    ..Thus, our data uncover a fundamental role of an endogenous antimicrobial peptide in breaking innate tolerance to self-DNA and suggest that this pathway may drive autoimmunity in psoriasis...
  35. pmc Deepening our understanding of immune sentinels in the skin
    Frank O Nestle
    St John s Institute of Dermatology, Division of Genetics and Molecular Medicine, King s College London School of Medicine, London, United Kingdom
    J Clin Invest 117:2382-5. 2007
    ..These studies provide the basis for better insight into the role of important immune sentinels contributing to the maintenance of skin tissue homeostasis and lay the foundation for future studies of the skin immune system...
  36. ncbi request reprint A new lease on life for dendritic cell vaccines?
    Frank O Nestle
    Nat Biotechnol 24:1483-4. 2006
  37. ncbi request reprint Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma
    Martin Kleinhans
    Department of Dermatology, University of Zurich Medical School, Switzerland
    Blood 101:1487-93. 2003
    ..These results suggest that expression of CCR3 and its ligand eotaxin/CCL11 plays a role in the recruitment and retention of CD30(+) malignant T cells to the skin...
  38. ncbi request reprint Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors
    Andreas Trojan
    Division of Oncology, Department of Internal Medicine, University Hospital Zurich, Ramistrasse 100, 8091, Switzerland
    Lung Cancer 36:151-8. 2002
    ..The results of our study indicate that Ep-CAM specific precursor CTL can be expanded in vitro and a specific T cell response against this epitope can be elicited in patients at various stages of lung cancer...
  39. ncbi request reprint Real-time polymerase chain reaction monitoring of epithelial cell adhesion molecule-induced T-cell stimulation in patients with lung cancer and healthy individuals using LightCycler technology
    Andreas Trojan
    Division of Oncology, Department of Internal Medicine, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    J Immunother 25:264-8. 2002
    ..Our study indicates that quantitative polymerase chain reaction may be a supplement to chromium-release assay for monitoring in vitro expanded CTL precursor reactivity...
  40. ncbi request reprint From inflammation to neoplasia: new concepts in the pathogenesis of cutaneous lymphomas
    Gunter Burg
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Recent Results Cancer Res 160:271-80. 2002
    ..g. environmental foreign antigens, bacterial superantigen, and/or endogenous factors, e.g. autocrine cytokine loops, CD40/CD40L and B7/CD28 interaction...
  41. ncbi request reprint Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells
    Takashi Murakami
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 62:7328-34. 2002
    ..Thus, CXCR4 plays a potentially important role in promoting organ-selective metastasis, possibly by stimulating tumor adhesion to microvascular endothelial cells and by enhancing the growth of tumor cells under stress...
  42. ncbi request reprint High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma
    Gunther F L Hofbauer
    Department of Dermatology, University Hospital Zurich, Switzerland
    J Immunother 27:73-8. 2004
    ..However, no statistically significant correlation between loss of these antigens in individual primary tumors and negative impact on overall survival was found in our cohort...
  43. pmc Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha
    Onur Boyman
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, CH 8091, Switzerland
    J Exp Med 199:731-6. 2004
    ..These findings underline the importance of resident immune cells in psoriasis and will have implications for new therapeutic strategies for psoriasis and other T cell-mediated diseases...
  44. pmc Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
    Brian J Nickoloff
    Skin Disease Research Laboratory and Cardinal Bernardin Cancer Center, Loyola University of Chicago, Medical Center, Maywood, Illinois 60153, USA
    J Clin Invest 113:1664-75. 2004
    ..Such strategic transition from serendipity to the use of novel selective agents aimed at defined targets in psoriatic lesions is moving rapidly from research benches to the bedsides of patients with this chronic and debilitating disease...
  45. ncbi request reprint Antigen specific immunotherapy: Quo vadis?
    Frank O Nestle
    Swiss Med Wkly 135:211. 2005